HR Execs on the Move

IM Cannabis

www.imcannabis.com

 
IM Cannabis (IMC) is one of the world`s pioneering medical-grade cannabis companies, with operations in Israel, across Europe, and Canada. Over the past decade, IMC has established its premium medical cannabis brand, comprising a full spectrum of products known for their quality, consistency, and purity, such as ROMA, TEL AVIV and LONDON. In Europe, IMC has established a fully operational, vertically integrated medical cannabis business, spearheaded by its EU-GMP certified distribution arm in Germany and augmented by strategic alliances with certified pan-EUGMP certified suppliers. To this end, IMC has formed strong strategic alliances within the international medical cannabis industry, aiming for a ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Itay Vago
Chief Financial Officer Profile

Similar Companies

UDG Healthcare plc

UDG Healthcare plc, formerly United Drug, is a Dublin-based international company and partner to the healthcare industry, providing clinical, commercial, communication and packaging services.

Paramount Pharmacies Limited

Paramount Pharmacies Limited is a New Waterford, NS-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Signature Pharmacy

Signature Pharmacy is a Winter Park, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sanofi Genzyme

Sanofi Genzyme, the specialty care business unit of Sanofi, focuses on rare diseases, multiple sclerosis, oncology, and immunology. We help people with debilitating and complex conditions that are often difficult to diagnose and treat. Our approach is shaped by our experience developing highly specialized treatments and forging close relationships with physician and patient communities. We are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world.

Immunic

Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn`s disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, is targeted for development in psoriasis and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction.